Holen Sie sich die Stockscreener-App
61.46
0.95%
0.584
Schlusskurs vom Vortag:
$60.88
Offen:
$60.95
24-Stunden-Volumen:
26,888
Relative Volume:
0.02
Marktkapitalisierung:
$8.84B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-766.63M
KGV:
-10.77
EPS:
-5.7051
Netto-Cashflow:
$-712.55M
1W Leistung:
+2.74%
1M Leistung:
+12.61%
6M Leistung:
+40.29%
1J Leistung:
+96.99%
1-Tages-Spanne:
$60.95
$61.39
1-Wochen-Bereich:
$58.51
$62.78
52-Wochen-Spanne:
$28.09
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
61.39 | 8.76B | 0 | -766.63M | -712.55M | -5.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.04 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.53 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.40 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily
Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance
What is the target price for Vaxcyte Inc stock2026 Momentum Check & AI Forecasted Entry/Exit Points - baoquankhu1.vn
PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vaxcyte CAO Sells $180,000 in Company Stock - National Today
Vaxcyte CAO Sells $180,000 in Stock - National Today
Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan
Vaxcyte to Present at Annual Healthcare Conference - National Today
Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus - AD HOC NEWS
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm
Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan
Vaxcyte (PCVX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI
PCVX Should I Buy - Intellectia AI
Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan
James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan
Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener
Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st
Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net
Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360
Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network
Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st
Responsive Playbooks and the PCVX Inflection - Stock Traders Daily
Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics
PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI
JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus
Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus
Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cowan Elvia | SVP, Finance & CAO |
Apr 07 '26 |
Sale |
60.00 |
3,000 |
180,000 |
28,975 |
0.62%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):